Cargando…

Skeletal muscle density is an independent predictor of diffuse large B‐cell lymphoma outcomes treated with rituximab‐based chemoimmunotherapy

BACKGROUND: While much cancer research focuses on tumours and their microenvironment, malignancies cause widespread physiologic changes. Cancer and treatment‐related sarcopenia, measured with quantitative imaging or as a decrease in overall body mass, are indicative of poor prognosis in elderly diff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chu, Michael P., Lieffers, Jessica, Ghosh, Sunita, Belch, Andrew, Chua, Neil S., Fontaine, Amelie, Sangha, Randeep, Turner, Robert A., Baracos, Vickie E., Sawyer, Michael B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5377388/ https://www.ncbi.nlm.nih.gov/pubmed/27897411 http://dx.doi.org/10.1002/jcsm.12161

Ejemplares similares

Skeletal Muscle Radio-Density Is an Independent Predictor of Response and Outcomes in Follicular Lymphoma Treated with Chemoimmunotherapy
por: Chu, Michael P., et al.
Publicado: (2015)

Delayed COVID-19 Respiratory Failure in Patients with Lymphoma on Rituximab-based Chemoimmunotherapy
por: Hoffmann, Marc S., et al.
Publicado: (2021)

Muscle and Adipose Wasting despite Disease Control: Unaddressed Side Effects of Palliative Chemotherapy for Pancreatic Cancer
por: Klassen, Pamela N., et al.
Publicado: (2023)

Concurrent depletion of skeletal muscle, fat, and left ventricular mass in patients with cirrhosis of the liver
por: Kazemi‐Bajestani, Seyyed Mohammad Reza, et al.
Publicado: (2015)

Small RNAome profiling from human skeletal muscle: novel miRNAs and their targets associated with cancer cachexia
por: Narasimhan, Ashok, et al.
Publicado: (2017)

Subcutaneous adiposity is an independent predictor of mortality in cancer patients
por: Ebadi, Maryam, et al.
Publicado: (2017)

Clinicopathological analysis of primary refractory diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy
por: Suzuki, Tomotaka, et al.
Publicado: (2021)

Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience
por: Suleman, Adam, et al.
Publicado: (2022)

What Influences the Choice of Ibrutinib–Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
por: Bravaccini, Sara, et al.
Publicado: (2020)

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
por: Shanafelt, Tait D., et al.
Publicado: (2022)

Lean body mass as an independent determinant of dose‐limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens
por: Ali, Raafi, et al.
Publicado: (2016)

Rapid atrophy of cardiac left ventricular mass in patients with non‐small cell carcinoma of the lung
por: Kazemi‐Bajestani, Seyyed Mohammad Reza, et al.
Publicado: (2019)

R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma
por: Lee, Hong Ghi, et al.
Publicado: (2014)

Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma
por: Kambhampati, Swetha, et al.
Publicado: (2022)

Differentially expressed alternatively spliced genes in skeletal muscle from cancer patients with cachexia
por: Narasimhan, Ashok, et al.
Publicado: (2017)

Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022)

Chemoimmunotherapy as long-term maintenance therapy for cancer
por: Egilmez, Nejat K., et al.
Publicado: (2012)

Intratumoral T‐cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B‐cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R‐CHOP) chemoimmunotherapy
por: Shanavas, Mohamed, et al.
Publicado: (2021)

Chemoimmunotherapy with rituximab, cyclophosphamide and prednisolone in IgM paraproteinemic neuropathy: evidence of sustained improvement in electrophysiological, serological and functional outcomes
por: Colchester, Nancy T. H., et al.
Publicado: (2020)

Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma
por: Ribrag, Vincent, et al.
Publicado: (2022)

Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)
por: González-Rincón, Julia, et al.
Publicado: (2021)

Pitfalls in defining and quantifying cachexia
por: Baracos, Vickie E.
Publicado: (2011)

Psoas as a sentinel muscle for sarcopenia: a flawed premise
por: Baracos, Vickie E.
Publicado: (2017)

Novel, First-in-Human, Oral PCLX-001 Treatment in a Patient with Relapsed Diffuse Large B-Cell Lymphoma
por: Sangha, Randeep, et al.
Publicado: (2022)

Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma
por: Prado, C M M, et al.
Publicado: (2012)

Reduced-Intensity Anthracycline-Free Chemoimmunotherapy in Elderly Patients With Newly Diagnosed or Relapsed Diffuse Large B-Cell Lymphoma
por: Yohannan, Binoy, et al.
Publicado: (2023)

Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy
por: Yuen, Hiu Lam Agnes, et al.
Publicado: (2020)

Analysis of Data on Fludarabine, Cyclophosphamide, and Rituximab Chemoimmunotherapy for Chronic Lymphocytic Leukemia Shows High Patient Heterogeneity and the Need for More Consideration of Individualized Treatment
por: Xu, Xiaoli, et al.
Publicado: (2022)

MAPK signaling regulates the efficacy of chemoimmunotherapy
por: Ghiringhelli, François
Publicado: (2022)

Poor Physical Function as a Marker of Sarcopenia in Adults with Class II/III Obesity
por: Johnson Stoklossa, Carlene A, et al.
Publicado: (2017)

Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China
por: Li, Zengjun, et al.
Publicado: (2015)

Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin’s lymphoma: a phase II, non-randomized controlled trial
por: Hochberg, Jessica, et al.
Publicado: (2022)

Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery
por: Lieffers, J R, et al.
Publicado: (2012)

The Role of Intestinal Microbiota in Development of Irinotecan Toxicity and in Toxicity Reduction through Dietary Fibres in Rats
por: Lin, Xiaoxi B., et al.
Publicado: (2014)

Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma
por: Merryman, Reid W., et al.
Publicado: (2023)

Complete response of metastatic gastric cancer to chemoimmunotherapy
por: Ina, Kenji, et al.
Publicado: (2017)

Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy
por: Wang, Tianqi, et al.
Publicado: (2021)

Targeted delivery of liposomal chemoimmunotherapy for cancer treatment
por: Liu, Yusheng, et al.
Publicado: (2022)

Altered cancer cell metabolism and cachexia: Calculating the energetic cost of cancer
por: Friesen, Douglas, et al.
Publicado: (2014)

Primary breast diffuse large B-cell lymphoma in the era of rituximab
por: Zhang, Na, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ve26kd58blhg645cjevoc3k6kr